Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.62 |
| ▸ | BRD4 | O60885 | 15/20 | 0.59 |
| ▸ | PLK1 | P53350 | 15/20 | 0.59 |
| ▸ | BRDT | Q58F21 | 10/20 | 0.59 |
| ▸ | VRK2 | Q86Y07 | 2/20 | 0.59 |
| ▸ | VRK1 | Q99986 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.59 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.59 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.59 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.59 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.52 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21527053 | 1.00 | RPS6KA3 (0.62) | RPS6KA3BRD4PLK1BRDTVRK2 | |
| SCHEMBL21916321 | 0.90 | PLK1 (0.68) | RPS6KA3BRD4PLK1BRDTCSNK1A1 | |
| SCHEMBL861947 | 0.90 | PLK1 (0.68) | RPS6KA3BRD4PLK1BRDTCSNK1A1 | |
| SCHEMBL12956561 | 0.87 | RPS6KA3 (0.62) | RPS6KA3BRD4PLK1BRDTVRK2 | |
| SCHEMBL862111 | 0.86 | PLK1 (0.77) | RPS6KA3BRD4PLK1BRDTPLK3 | |
| SCHEMBL10065440 | 0.85 | BRD4 (0.46) | RPS6KA3BRD4PLK1BRDTVRK2 | |
| SCHEMBL861752 | 0.83 | PLK1 (0.51) | RPS6KA3BRD4PLK1BRDTPLK3 | |
| SCHEMBL21527107 | 0.83 | PLK1 (0.52) | RPS6KA3BRD4PLK1BRDTCSNK1A1 | |
| SCHEMBL862080 | 0.81 | PLK1 (0.85) | RPS6KA3BRD4PLK1BRDTCSNK1A1 | |
| SCHEMBL12323787 | 0.81 | PLK1 (0.78) | RPS6KA3BRD4PLK1BRDTCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3560499-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-8445675-B2 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8445675-B2 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-8143247-B2 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143247-B2 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | PLK4, TK1, POLK | RPS6KA3 253/4885BRD4 4296/4885PLK1 6/4885 |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | RPS6KA3 205/4885BRD4 2468/4885PLK1 162/4885 |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | RPS6KA3 205/4885BRD4 2468/4885PLK1 162/4885 |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | RPS6KA3 911/4885BRD4 4860/4885PLK1 2334/4885 |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | QDPR, DHPS, DHODH | RPS6KA3 473/4885BRD4 4628/4885PLK1 4090/4885 |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | QDPR, F5, F12 | RPS6KA3 911/4885BRD4 4860/4885PLK1 2334/4885 |
| US-20080293944-A1 | Piperazinyl Compounds | QDPR, DHPS, DPYD | RPS6KA3 122/4885BRD4 4157/4885PLK1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.